Get the Stockscreener App
0.3562
0.39%
-0.0014
Bioatla Inc stock is traded at $0.3562, with a volume of 496.21K.
It is down -0.39% in the last 24 hours and up +4.37% over the past month.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
See More
Previous Close:
$0.3576
Open:
$0.3663
24h Volume:
496.21K
Relative Volume:
0.86
Market Cap:
$20.92M
Revenue:
-
Net Income/Loss:
$-123.46M
P/E Ratio:
-0.1375
EPS:
-2.59
Net Cash Flow:
$-104.11M
1W Performance:
-3.13%
1M Performance:
+4.37%
6M Performance:
-12.72%
1Y Performance:
-80.21%
1-Day Range:
$0.35
$0.3814
1-Week Range:
$0.35
$0.397
52-Week Range:
$0.2601
$2.525
Bioatla Inc Stock (BCAB) Company Profile
Name
Bioatla Inc
Sector
Industry
Phone
858-558-0708
Address
11085 TORREYANA ROAD, SAN DIEGO
Compare BCAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
0.3562 | 22.82M | 0 | -123.46M | -104.11M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Nov-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-15-22 | Initiated | JMP Securities | Mkt Outperform |
| May-05-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-21-22 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Jun-28-21 | Initiated | ROTH Capital | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | BTIG Research | Buy |
| Jan-11-21 | Initiated | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | JP Morgan | Overweight |
| Jan-11-21 | Initiated | Jefferies | Buy |
View All
Bioatla Inc Stock (BCAB) Latest News
What analysts say about BioAtla Inc. stock outlookTrade Entry Summary & Reliable Price Breakout Alerts - beatles.ru
BioAtla Inc. Recovery Hinges on Volume Breakout2025 Fundamental Recap & High Accuracy Trade Signal Alerts - beatles.ru
Will BioAtla Inc. see short term momentumJuly 2025 WrapUp & Daily Profit Focused Stock Screening - Newser
Visualizing BioAtla Inc. stock with heatmapsInsider Buying & Reliable Breakout Forecasts - Newser
Detecting support and resistance levels for BioAtla Inc.July 2025 Setups & High Yield Equity Trading Tips - Newser
Has BioAtla Inc. formed a bullish divergenceJuly 2025 Levels & Technical Buy Zone Confirmations - Newser
BioAtla Inc. stock momentum explained2025 Key Lessons & Weekly Top Gainers Alerts - Newser
Is BioAtla Inc. stock bottoming outPortfolio Performance Summary & Risk Controlled Swing Alerts - Newser
Is it time to cut losses on BioAtla Inc.Profit Target & Low Risk Entry Point Guides - Newser
BioAtla Inc. Tests 50 Day MA After Sharp DeclineWeekly Investment Report & Weekly Watchlist for Hot Stocks - Newser
Technical Models Suggest BioAtla Inc. May Rebound SoonDay Trade & AI Enhanced Trading Alerts - beatles.ru
How to forecast BioAtla Inc. trends using time seriesRate Hike & Free Community Supported Trade Ideas - Newser
How sentiment analysis helps forecast BioAtla Inc.Market Trend Review & Smart Investment Allocation Insights - Newser
Using data filters to optimize entry into BioAtla Inc.2025 Retail Activity & Risk Managed Investment Signals - Newser
Sector ETF performance correlation with BioAtla Inc.Gap Up & Community Consensus Trade Alerts - Newser
Can BioAtla Inc. rally from current levelsEarnings Summary Report & Accurate Entry/Exit Alerts - Newser
BioAtla Inc. Stock Performance After Earnings: Historical InsightsTrade Volume Report & Risk Controlled Daily Plans - Newser
BioAtla’s Earnings Call: Positive Clinical Progress Amid Financial Challenges - MSN
BioAtla Inc. Testing Reversal Zone on Weekly Chart2025 Top Decliners & Free Long-Term Investment Growth Plans - classian.co.kr
Combining price and volume data for BioAtla Inc.Stop Loss & High Accuracy Swing Entry Alerts - Newser
What technical models suggest about BioAtla Inc.’s comebackJuly 2025 Rallies & Verified Entry Point Detection - Newser
Exit strategy if you’re trapped in BioAtla Inc.Quarterly Trade Summary & Risk Managed Investment Signals - Newser
BioAtla downgraded to Market Perform from Outperform at Citizens JMP - MSN
JMP Securities Reiterates “Market Perform” Rating for BioAtla (NASDAQ:BCAB) - Defense World
BioAtla (NASDAQ:BCAB) Rating Lowered to Market Perform at Citizens Jmp - Defense World
BioAtla's BCAB Downgraded to Market Perform by JMP Securities - AInvest
HC Wainwright Predicts BioAtla’s Q3 Earnings (NASDAQ:BCAB) - Defense World
BioAtla’s SWOT analysis: oncology biotech’s stock faces cash crunch By Investing.com - Investing.com South Africa
BioAtla’s SWOT analysis: oncology biotech’s stock faces cash crunch - Investing.com
Citizens JMP Downgrades BioAtla(BCAB.US) to Hold Rating - 富途牛牛
BioAtla stock downgraded by Citizens JMP on cash concerns - Investing.com Canada
Will BioAtla Inc. see short term momentum [2025 Market Trends]Accurate Intraday Trading Signals - Newser
Why BioAtla Inc. stock attracts strong analyst attentionDay Trading Plan with Entry Risk Management - Newser
Analysts Apply Wyckoff Model to BioAtla Inc. StockBuy Low Sell High Stock Watch Strategy in Focus - 선데이타임즈
BioAtla, Inc. (NASDAQ:BCAB) Q2 2025 Earnings Call Transcript - Insider Monkey
Bioatla Inc Stock (BCAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):